Analysis of reasons for not implementing pathogen inactivation for platelet concentrates

Transfusion Clinique et Biologique

Volumn 20, Issue 2, 2013, Pages 158-164

  Lozano, M ^a   Cid, J ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Amotosalen; Pathogen inactivation; Platelets; UVA

Indexed keywords

AMOTOSALEN; THROMBOCYTE CONCENTRATE;

BLEEDING; BLOOD SAFETY; EUROPEAN UNION; HUMAN; ILLUMINATION; MICROBIAL CONTAMINATION; RECIPIENT; RISK ASSESSMENT; SHORT SURVEY; THROMBOCYTE FUNCTION; ULTRAVIOLET A RADIATION;

BACTEREMIA; BLOOD PLATELETS; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; HEMORRHAGE; HUMANS; META-ANALYSIS AS TOPIC; MICROBIAL VIABILITY; MULTICENTER STUDIES AS TOPIC; PHOTOCHEMISTRY; PHOTOSENSITIZING AGENTS; PLATELET ACTIVATION; PLATELET TRANSFUSION; PLATELETPHERESIS; PSORALENS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ULTRAVIOLET RAYS; VIREMIA;

EID: 84878113969     PISSN: 12467820     EISSN: 19538022     Source Type: Journal    
DOI: 10.1016/j.tracli.2013.02.017     Document Type: Short Survey

References (47)

1. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999, 39:1160-1168.
2. Lozano M. Pathogen-inactivation technologies for blood components. Blood component preparation: from benchtop to bedside 2011, 247-270. AABB Press, Bethesda, Maryland. M. Blajchman, J. Cid, M. Lozano (Eds.).
3. Garraud O. Risques connus et impact de mesures prises sur ces risques en transfusion sanguine. Transfus Clin Biol 2011, 18:463-467.
4. Kleinman S., Reed W., Stassinopoulos A. A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States. Transfusion 2013, [Epub ahead of print]. 10.1111/j.1537-2995.2012.03928.x.
5. Novak M. Preservation of stored blood with sulfanilamide. J Am Med Assoc 1939, 113:2227-2229.
6. Benjamin R., Eder A.F. Bacterial contamination of platelet products. Platelet transfusion therapy 2013, AABB Press, Bethesda, MD. J. Sweeney, M. Lozano (Eds.).
7. Walther-Wenke G., Schrezenmeier H., Deitenbeck R., Geis G., Burkhart J., Hochsmann B., et al. Screening of platelet concentrates for bacterial contamination: spectrum of bacteria detected, proportion of transfused units, and clinical follow-up. Ann Hematol 2010, 89:83-91.
8. American Association of Blood Banks Standards for blood banks and transfusion services 2003, American Association of Blood Banks, Bethesda, MD, p. 13. 22nd ed.
9. Eder A.F., Kennedy J.M., Dy B.A., Notari E.P., Skeate R., Bachowski G., et al. Limiting and detecting bacterial contamination of apheresis platelets: inlet-line diversion and increased culture volume improve component safety. Transfusion 2009, 49:1554-1563.
10. Dunbar N.M., Kreuter J.D., Marx-Wood C.R., Dumont L.J., Szczepiorkowski Z.M. Routine bacterial screening of apheresis platelets on Day 4 using a rapid test: a 4-year single-center experience. Transfusion 2013, [Epub ahead of print]. 10.1111/trf.12083.
11. Vamvakas E.C. Risk-reduction strategies for platelet transfusion in the United States. ScientificWorldJournal 2011, 11:624-640.
12. Murphy W.G., Foley M., Doherty C., Tierney G., Kinsella A., Salami A., et al. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang 2008, 95:13-19.
13. Glynn S.A., Busch M.P., Dodd R.Y., Katz L.M., Stramer S.L., Klein H.G., et al. Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century. Transfusion 2013, 53:438-454.
14. Blajchman M.A. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Clin Biol 2009, 16:70-74.
15. Petersen L.R., Epstein J.S. Problem solved? West Nile virus and transfusion safety. N Engl J Med 2005, 353:516-517.
16. Biggerstaff B.J., Petersen L.R. Estimated risk of transmission of the West Nile virus through blood transfusion in the US, 2002. Transfusion 2003, 43:1007-1017.
17. Pealer L.N., Marfin A.A., Petersen L.R., Lanciotti R.S., Page P.L., Stramer S.L., et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003, 349:1236-1245.
18. Cazenave J.P. Inactivation des pathogènes des concentrés plaquettaires : expérience française. Transfus Clin Biol 2011, 18:478-484.
19. Irsch J., Lin L. Pathogen Inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system. Transfus Med Hemother 2011, 38:19-31.
20. Ciaravino V., McCullough T., Dayan A.D. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol 2001, 20:533-550.
21. Corash L.M., Paton V., Wages D., Rheinschmidt M., Porter S., Cimino G., et al. S-59 Clearance and kinetics after transfusion of platelets treated with Helinx™ technology. Transfusion 2000, 40:37S.
22. Tice R.R., Gatehouse D., Kirkland D., Speit G. The pathogen reduction treatment of platelets with S-59 HCl (Amotosalen) plus ultraviolet A light: genotoxicity profile and hazard assessment. Mutat Res 2007, 630:50-68.
23. Ciaravino V., McCullough T., Cimino G. The role of toxicology assessment in transfusion medicine. Transfusion 2003, 43:1481-1492.
24. Ciaravino V., Hanover J., Lin L., Sullivan T., Corash L. Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats. Transfusion 2009, 49:985-994.
25. Lin L., Conlan M.G., Tessman J., Cimino G., Porter S. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Transfusion 2005, 45:1610-1620.
26. Osselaer J.C., Messe N., Hervig T., Bueno J., Castro E., Espinosa A., et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008, 48:1061-1071.
27. Osselaer J.C., Cazenave J.P., Lambermont M., Garraud O., Hidajat M., Barbolla L., et al. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008, 94:315-323.
28. Rasongles P., Angelini-Tibert M.F., Simon P., Currie C., Isola H., Kientz D., et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in île de La Reunion. Transfusion 2009, 49:1083-1091.
29. van Rhenen D.J., Vermeij J., Mayaudon V., Hind C., Lin L., Corash L. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000, 79:206-214.
30. Picker S.M., Speer R., Gathof B.S. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004, 44:320-329.
31. Lozano M., Galan A., Mazzara R., Corash L., Escolar G. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions. Transfusion 2007, 47:666-671.
32. Snyder E., Raife T., Lin L., Cimino G., Metzel P., Rheinschmidt M., et al. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004, 44:1732-1740.
33. Slichter S.J., Raife T.J., Davis K., Rheinschmidt M., Buchholz D.H., Corash L., et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006, 46:731-740.
34. van Rhenen D., Gulliksson H., Cazenave J.P., Pamphilon D., Ljungman P., Kluter H., et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003, 101:2426-2433.
35. McCullough J., Vesole D.H., Benjamin R.J., Slichter S.J., Pineda A., Snyder E., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004, 104:1534-1541.
36. Snyder E., McCullough J., Slichter S.J., Strauss R.G., Lopez-Plaza I., Lin J.S., et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005, 45:1864-1875.
37. Corash L., Sherman C.D. Evaluation of platelet transfusion clinical trials. Br J Haematol 2011, 153:529-531.
38. AuBuchon J.P. Breathing easy with pathogen inactivation. Blood 2011, 117:749-751.
39. Janetzko K., Cazenave J.P., Kluter H., Kientz D., Michel M., Beris P., et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005, 45:1443-1452.
40. Kerkhoffs J.L., van Putten W.L., Novotny V.M., te Boekhorst P.A., Schipperus M.R., Zwaginga J.J., et al. Clinical effectiveness of leukoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010, 150:209-217.
41. Slichter S.J., Kaufman R.M., Assmann S.F., McCullough J., Triulzi D.J., Strauss R.G., et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010, 362:600-613.
42. Lozano M., Knutson F., Tardivel R., Cid J., Maymo R.M., Lof H., et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011, 153:393-401.
43. Vamvakas E.C. Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 2011, 51:1058-1071.
44. Vamvakas E.C. Assessment of haemostasis in platelet transfusion clinical trials with differential follow-up. Vox Sang 2012, 103:180-181.
45. Cid J., Escolar G., Lozano M. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 2012, 103:322-330.
46. Osselaer J.C., Doyen C., Defoin L., Debry C., Goffaux M., Messe N., et al. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009, 49:1412-1422.
47. Cazenave J.P., Isola H., Kientz D. Pathogen inactivation of platelets. Platelet transfusion therapy 2013, AABB Press, Bethesda, MD. J. Sweeney, M. Lozano (Eds.).